You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
維亞生物(1873.HK)漲超5% 孵化公司與阿斯利康就口服PCSK9抑制劑項目全球權益達成收購協議
格隆匯 09-18 10:26
格隆匯9月18日丨維亞生物(1873.HK)現報9.55港元,漲5.88%,暫成交4161萬港元,最新總市值181億港元。昨日(17日),由維亞生物投資孵化的生物醫藥公司Dogma Therapeutics與阿斯利康就收購其口服PCSK9項目全球權益達成協議。阿斯利康將支付Dogma首付款,並在全球監管和商業里程碑達成後,向Dogma支付里程碑款項。此外據悉,維亞生物曾公佈業績稱,中期經調整淨利潤同比增長25.5%至約1.24億元(人民幣,下同),淨虧損5.3億元,上年同期為淨利潤4649.6萬元,中期股息每股0.017港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account